Company Overview

Tenon Medical, Inc. is a U.S.-based medical device company focused on the development and commercialization of solutions for sacroiliac (SI) joint disorders, operating within the orthopedic medical device and spine care industries. The company’s core product is the Catamaran® SI Joint Fixation System, a minimally invasive implant designed to stabilize and fuse the SI joint using a posterior surgical approach. Revenue is primarily generated through sales of this system to hospitals, ambulatory surgery centers, and spine-focused physicians.

The company positions itself as a differentiated player in the SI joint fusion market by emphasizing a less invasive posterior approach compared with traditional lateral techniques, aiming to reduce tissue disruption and procedural complexity. Tenon Medical was founded to commercialize technology originally developed to address unmet clinical needs in chronic low back pain associated with SI joint dysfunction. The company became publicly traded in 2022, marking a transition from development-stage operations to early-stage commercial execution.

Business Operations

Tenon Medical operates as a single-segment business focused on the development, manufacturing oversight, and commercialization of its SI joint fixation technology. Its revenue is generated through the sale of the Catamaran® SI Joint Fixation System, including implants and associated surgical instruments. Manufacturing is conducted through third-party contract manufacturers, while the company maintains internal capabilities for product development, regulatory affairs, and commercialization.

Commercial operations are concentrated in the United States, where Tenon Medical employs a direct sales force supplemented by independent distributors in select territories. The company does not report material international revenue, and public disclosures indicate no diversified operating segments or material subsidiaries. Data inconclusive based on available public sources regarding any active joint ventures or equity-method investments.

Strategic Position & Investments

Tenon Medical’s strategic direction centers on expanding surgeon adoption of posterior SI joint fusion techniques and increasing market awareness of its Catamaran system through clinical education and targeted commercialization. Growth initiatives focus on expanding the U.S. sales footprint, generating additional clinical evidence, and pursuing broader reimbursement coverage from public and private payers.

The company has not disclosed any material acquisitions or large-scale equity investments since becoming public. Strategic investment has primarily been internal, directed toward product refinement, regulatory compliance, and post-market clinical data development. Public filings do not indicate ownership of notable subsidiaries or a diversified investment portfolio beyond its core technology platform.

Geographic Footprint

Tenon Medical is headquartered in the United States, with corporate offices located in California. Its commercial and operational activities are primarily domestic, with product sales and clinical usage concentrated in U.S. healthcare facilities.

While the company has indicated long-term interest in international markets, public disclosures show that operations, revenue, and regulatory focus remain overwhelmingly U.S.-centric. Data inconclusive based on available public sources regarding active commercial operations or regulatory approvals outside the United States.

Leadership & Governance

Tenon Medical is led by a management team with experience in medical devices, commercialization, and public company governance. The leadership’s stated strategic vision emphasizes disciplined commercialization, clinical validation, and responsible capital management as the company scales its operations.

Key executives include:

• Steven M. Foster – President and Chief Executive Officer
• Steven M. Foster – Chairman of the Board
• Matthew C. Glover – Chief Financial Officer

Public disclosures identify Mr. Foster as the company’s founder and a central figure in its strategic and operational leadership. Data inconclusive based on available public sources regarding additional executive appointments or recent changes beyond those listed above.